



Docket No.: 05432/000J951-US0
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Connie Sanchez et al.

Application No.: 10/021,126

Confirmation No.: 7268

Filed: December 12, 2001

Art Unit: 1614

For: TREATMENT OF NEUROTIC DISORDERS

Examiner: F. Krass

INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, attached hereto is a copy of Form PTO/SB/08 and copies of the documents listed thereon.

Reference CG to the Information Disclosure Statement provides the procedure and results of the guinea pig ileum experiment and the tabulated results of the footshock-induced ultrasonic vocalization experiment referred to in Sanchez, *Eur. J. Pharm.*, 465:155-158 (2003).

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO/SB/08) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO/SB/08 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner

does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.


No fee is believed due with this Information Disclosure Statement. However, if any fee is due, the Commissioner is authorized to charge it up to \$2,000.00 to Deposit Account No. 04-0100.

Dated: February 16, 2005

Respectfully submitted,

By 
Jay P. Lessler

Registration No.: 41,151
(212) 527-7700
(212) 527-7701 (Fax)
Attorneys/Agents For Applicant



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/021,126-Conf. #7268
				Filing Date	December 12, 2001
				First Named Inventor	Connie Sanchez
				Art Unit	1614
				Examiner Name	F. Krass
Sheet	1	of	1	Attorney Docket Number	05432/000J951-USO

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CA ✓	P. Auquier et al., <i>Int. J. Psychiatr. Clin. Pract.</i> 7:259-268 (2003)		
	CB ✓	E. Bien et al., <i>Behav. Pharmacol.</i> 14:S37 (2003).		
	CC	E. W. Fish et al., <i>J. Pharmacol. Exp. Ther.</i> October 30, 2003, Fast Forward publ. as DOI: 10.1124/jpet.103.058206 (2004).		
	CD	C. Sanchez et al., <i>Psychopharmacology</i> 167:353-362 (2003)		
	CE ✓	C. Sanchez, <i>Behav. Pharmacol.</i> 14:465-470 (2003)		
	CF ✓	C. Sanchez et al. <i>Psychopharmacology (Berl)</i> . (2004), "Escitalopram versus citalopram: the surprising role of the R-enantiomer".		
	CG	Declaration of Connie Sanchez.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

The PTO did not receive the following
listed item(s) cite # CC

W:054 32/0001		Date Considered	
------------------	--	--------------------	--